[
  {
    "ts": null,
    "headline": "Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination",
    "summary": "Moderna (MRNA) shares were down almost 5% in recent trading on Friday after management provided an u",
    "url": "https://finnhub.io/api/news?id=0bc63e8f8ddfd9f12b6bae7b4272a205ecc282e3b02d989685ea680d8cd0c7af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760729535,
      "headline": "Moderna Shares Fall After Early Trial Update on mRNA-4359 Cancer Vaccine Combination",
      "id": 137165739,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) shares were down almost 5% in recent trading on Friday after management provided an u",
      "url": "https://finnhub.io/api/news?id=0bc63e8f8ddfd9f12b6bae7b4272a205ecc282e3b02d989685ea680d8cd0c7af"
    }
  },
  {
    "ts": null,
    "headline": "Moderna: More Downside In The Stock But The Cancer Vaccine Offers Potential",
    "summary": "Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn more about MRNA stock here.",
    "url": "https://finnhub.io/api/news?id=20a7ca1f5e3e655612b148b027368dcbdf187b13ed105dd1ed49a3c5ae04cd4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717330,
      "headline": "Moderna: More Downside In The Stock But The Cancer Vaccine Offers Potential",
      "id": 137129094,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2202893768/image_2202893768.jpg?io=getty-c-w1536",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn more about MRNA stock here.",
      "url": "https://finnhub.io/api/news?id=20a7ca1f5e3e655612b148b027368dcbdf187b13ed105dd1ed49a3c5ae04cd4b"
    }
  },
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA) Shareholder/Analyst Call Transcript",
    "summary": "Moderna, Inc. (NASDAQ:MRNA) Shareholder/Analyst Call October 17, 2025 12:00 PM EDTCompany ParticipantsKyle HolenLavina Talukdar - Senior VP & Head of...",
    "url": "https://finnhub.io/api/news?id=4ba3bc3df04ef0f9cb68f5f5e4ce78d2a06bca935386f2abe95c47ead5c25784",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717198,
      "headline": "Moderna, Inc. (MRNA) Shareholder/Analyst Call Transcript",
      "id": 137129095,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "Moderna, Inc. (NASDAQ:MRNA) Shareholder/Analyst Call October 17, 2025 12:00 PM EDTCompany ParticipantsKyle HolenLavina Talukdar - Senior VP & Head of...",
      "url": "https://finnhub.io/api/news?id=4ba3bc3df04ef0f9cb68f5f5e4ce78d2a06bca935386f2abe95c47ead5c25784"
    }
  },
  {
    "ts": null,
    "headline": "Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025",
    "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO […]",
    "url": "https://finnhub.io/api/news?id=71e19948742187574172ca8fb05120abf7d67ce3dac4b49df0a511ab075c500c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760709555,
      "headline": "Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025",
      "id": 137126226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO […]",
      "url": "https://finnhub.io/api/news?id=71e19948742187574172ca8fb05120abf7d67ce3dac4b49df0a511ab075c500c"
    }
  }
]